Acute Kidney Injury Therapeutics Pipeline 2018: Witnessing Strong Growth due to Increasing Research Funding
DUBLIN, July 5, 2018 /PRNewswire/ --
The "Acute Kidney Injury Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" report has been added to ResearchAndMarkets.com's offering.
The study analyzed that AKI therapeutics pipeline comprises approximately 40 drug candidates in different stages of development.
According to the research findings, a majority of the drug candidates for the treatment of AKI are being developed to be administered by the intravenous route. It has been observed that the drugs which are being administered through intravenous route have high efficacy because of their higher bioavailability.
AKI Therapeutics Pipeline has been Witnessing Significant Growth due to Increasing Research Funding
Various health organizations such as National Institute of Diabetes and Digestive and Kidney Diseases and Small Business Innovation Research (SBIR) program of the U.S. Small Business Administration (SBA) are strengthening the growth of AKI therapeutics pipeline. For instance, TheraSource LLC received a funding of $335,318 from SBIR for its research project aimed at demonstrating the feasibility of developing recombinant human milk fat globule epidermal growth factor rhMFG E, as a novel and effective therapeutic for treating patients suffering with AKI, associated with ischemia due to low renal perfusion.
Increase in Patents Approval for AKI therapeutics Candidates
There has been an increase in the number of patents approved for the development of drug candidates for the treatment of AKI. For instance, in October 2016, the USPTO issued U.S. Patent 9,464,114 to Arch BioPartners, entitled, Peptides that Block Leukocyte Recruitment and Methods of Use. This was the first patent issued protecting the composition and method of use for Metablok.
AKI Therapeutics Pipeline Marked by Various Technological Advancements
Most of the companies are developing innovative technologies for the synthesis or production of drug candidates for the treatment of AKI. For instance, Quark Pharmaceuticals Inc. is using an innovative technology platform for generation of chemically modified siRNA compounds and their delivery to the desired organs. These are particularly well-suited to exploit the potential of siRNA for therapeutic applications. Also, Silver Creek Pharmaceuticals Inc. is using smart growth factor technology platform for the development of growth factors that play an important role in development, maintenance of tissue homeostasis, and pathology of many disease states.
Some of the key players involved in the development of AKI therapeutics include Alloksys Life Sciences B.V., Stealth BioTherapeutics Inc., and Angion Biomedica Corp.
Key Topics Covered
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1 Pipeline Analysis by Phase
1.3.2 Pipeline Analysis by Molecule Type
1.3.3 Pipeline Analysis by Route of Administration
1.4 Key Stakeholders
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents
2.2.1.1 by industry participant
2.2.1.2 by company type
3. Executive Summary
4. Pipeline Outlook
4.1 Disease Overview
4.1.1 Classification of AKI
4.1.1.1 General classification
4.1.1.2 Classification based on daily urine excretion
4.1.1.3 RIFLE classification system for AKI
4.1.1.4 AKI network classification system
4.2 Causes and Risk Factors
4.2.1 Causes of AKI
4.2.1.1 Reduced blood flow to kidneys
4.2.1.2 Damage to kidneys
4.2.1.3 Obstruction to the drainage of kidneys
4.2.2 Risk Factors of AKI
4.3 Symptoms
4.3.1 Complications
4.4 Diagnosis
4.5 Treatment
4.5.1 Treatment of the Underlying Cause of AKI
4.5.2 Treatment of Symptoms/Complications Associated with AKI
4.6 Prevention
4.7 Epidemiology
4.8 Key Drivers
4.8.1 Research Funding from Various Agencies
4.8.2 No Approved Treatment
4.9 Key Barriers
4.9.1 Discontinuation of Drugs
4.10 Acute Kidney Injury Therapeutics Pipeline Analysis
4.10.1 Pipeline Analysis by Phase
4.10.2 Pipeline Analysis by Molecule Type
4.10.3 Pipeline Analysis by Route of Administration
4.10.4 Pipeline Analysis by Company
5. Acute Kidney Injury Therapeutics Pipeline Analysis by Phase (2018)
5.1 Phase III
5.1.1 RESCAP
5.1.1.1 Clinical trials
5.1.1.2 Grant
5.1.1.3 Patents
5.1.2 XX
5.1.2.1 Clinical trials
5.2 Phase II/III
5.2.1 Levosimendan
5.2.1.1 Clinical trials
5.2.2 XX
5.2.2.1 Clinical trials
5.3 Phase II
5.3.1 Elamipretide
5.3.1.1 Collaboration
5.3.1.2 Technology
5.3.2 XX
5.3.2.1 Clinical trials
5.3.3 XX
5.3.3.1 Pre-Clinical results
5.3.3.2 Clinical trials
5.3.4 XX
5.3.4.1 Clinical trials
5.3.4.2 Funding
5.3.5 XX
5.3.5.1 Pre-Clinical results
5.3.5.2 Clinical trials
5.3.5.3 Technology
5.3.6 XX
5.3.6.1 Clinical trials
5.3.6.2 Clinical trial results
5.3.6.3 Pre-Clinical results
5.3.6.4 Funding
5.3.6.5 Strategic developments
5.3.7 XX
5.3.7.1 Clinical trials
5.3.7.2 Clinical trial results
5.3.7.3 Strategic developments
5.3.8 XX
5.3.8.1 Clinical trials
5.4 Phase I/II
5.4.1 SBI-101
5.4.1.1 Clinical trials
5.4.1.2 Grants
5.5 Phase I
5.5.1 XX
5.5.1.1 Clinical trials
5.5.1.2 Clinical trial results
5.5.1.3 Technology
5.5.2 XX
5.5.3 XX
5.5.3.1 Clinical trials
5.5.4 XX
5.5.4.1 Pre-Clinical result
5.5.4.2 Clinical trials
5.5.4.3 Strategic developments
5.6 IND
5.6.1 XX
5.6.1.1 Pre-Clinical results
5.6.1.2 Patent
5.6.1.3 Technology
5.6.1.4 Strategic developments
5.7 Pre-Clinical
5.7.1 XX
5.7.1.1 Pre-Clinical results
5.7.1.2 Clinical trials
5.7.1.3 Collaboration
5.7.1.4 Patent
5.7.2 XX
5.7.2.1 Technology
5.7.3 XX
5.7.3.1 Technology
5.7.4 XX
5.7.4.1 Strategic developments
5.7.5 XX
5.7.5.1 Pre-Clinical results
5.7.6 XX
5.7.6.1 Strategic developments
5.7.7 XX
5.7.7.1 Pre- Clinical study
5.7.8 XX
5.7.8.1 Pre-Clinical trials
5.7.8.2 Patents
5.7.8.3 Other
5.7.9 XX
5.7.9.1 Pre-Clinical Result
5.7.10 XX
5.7.10.1 Patents
5.7.10.2 Technology
5.7.10.3 Strategic developments
5.7.11 XX
5.7.11.1 Pre-Clinical results
5.7.11.2 Strategic developments
5.7.12 XX
5.7.12.1 Pre-Clinical study
5.7.13 XX
5.7.13.1 Pre-Clinical result
5.7.14 XX
5.7.14.1 Pre-Clinical results
5.7.14.2 Technology
5.7.15 XX
5.7.16 XX
5.7.16.1 Pre-Clinical results
5.7.17 XX
5.7.17.1 Pre-Clinical results
5.7.18 XX
5.7.18.1 Pre-Clinical result
5.8 Discovery
5.8.1 XX
5.8.2 XX
5.8.2.1 Strategic developments
5.8.3 XX
5.8.3.1 Patents
5.9 Unknown
5.9.1 XX
5.9.1.1 Strategic developments
6. Clinical Trials Review
6.1 Clinical Trials by Region
6.2 Clinical Trials by Trial Status
7. Competitive Landscape
7.1 Key Players Benchmarking for AKI Therapeutics Pipeline
7.2 SWOT Analysis of AKI Therapeutics Pipeline
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats
8. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/zhbbfc/acute_kidney?w=5
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article